Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

Blood (2022) 139 (9): 1289–1301.

https://doi.org/10.1182/blood.2020008493

Published: 2022

Includes: Supplemental data

Journal Articles

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Christopher T Su, MD, Liying Chen, MS, Jason Chen, MD, Brian Parkin, MD, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica Campagnaro, MD, Josh Vo, PhD, Dan Robinson, PhD, Yi-Mi Wu, PhD, Moshe Talpaz, MD, Jennifer Yesil, MSc, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MDPhD, Veerabhadran Baladandayuthapani, PhD, J Christine Ye, MDMSc

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-134558

Published: 2020

Journal Articles

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

J Christine Ye, MDMSc, Liying Chen, Jason Chen, MD, Brian Parkin, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica L. Campagnaro, MD, Dan Robinson, PhD, Yi-Mi Wu, Moshe Talpaz, MD, Jennifer Yesil, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MD, Veerabhadran Baladandayuthapani

Blood (2019) 134 (Supplement_1): 4360.

https://doi.org/10.1182/blood-2019-124135

Published: 2019

Journal Articles

Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity

Blood (2014) 124 (21): 3414.

https://doi.org/10.1182/blood.V124.21.3414.3414

Published: 2014

Journal Articles

Mucin 20 (MUC20) Modulates Proteasome Assembly Chaperones through the c-MET Pathway and Is a Biomarker of Proteasome Inhibitor Sensitivity in Myeloma

Huihan Wang, MD, PhD, Veerabhadran Baladandayuthapani, PhD, Heather Yan Lin, PhD, Xiaobin Wang, MD, Bingzong Li, MD, PhD, Xing-Ding Zhang, PhD, Isere Kuiatse, PhD, Hua Wang, PhD, Dongmin Gu, MD, PhD, Liye Zhong, PhD, Wencai Ma, PhD, Richard E. Davis, MD, Robert Z. Orlowski, MD, PhD

Blood (2014) 124 (21): 274.

https://doi.org/10.1182/blood.V124.21.274.274

Published: 2014

Journal Articles

Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells

Amal A. El-Mabhouh, Mary L. Ayres, Elizabeth J. Shpall, Veerabhadran Baladandayuthapani, Michael J. Keating, William G. Wierda, Varsha Gandhi

Blood (2014) 123 (24): 3780–3789.

https://doi.org/10.1182/blood-2013-12-541433

Published: 2014

Includes: Supplemental data

Journal Articles

Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM)

Robert Z. Orlowski, M.D., Ph.D, Shadia Zaman, Ph.D., Sheeba K. Thomas, M.D., Raymond Alexanian, M.D., Jatin J. Shah, M.D., Donna M. Weber, M.D., Michael Wang, MD, Ashley N. Holloway, R.N., Veerabhadran Baladandayuthapani, Ph.D., Heather Yan Lin, Ph.D., Min Fu, Christine M. Stellrecht, Ph.D., Claudia Morales de Partovi, B.S., Varsha Gandhi, PhD

Blood (2013) 122 (21): 1953.

https://doi.org/10.1182/blood.V122.21.1953.1953

Published: 2013

Journal Articles

Expression Of Truncated Protein Tyrosine Phosphatase, Receptor Type, O (PTPROt) Influences Multiple Myeloma Sensitivity To Bortezomib Through Akt Signaling, and Is a Favorable Clinical Prognostic Factor

Hua Wang, Ph.D., Veerabhadran Baladandayuthapani, Ph.D., Zhiqiang Wang, Ph.D., Jiexin Zhang, Heather Yan Lin, Ph.D., Richard E. Davis, M.D., Lin Yang, Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 2520.

https://doi.org/10.1182/blood.V122.21.2520.2520

Published: 2013

Journal Articles

Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia

Rupin A Shah, M.B.B.S, Satyajit Mohite, M.B.B.S., Veerabhadran Baladandayuthapani, Ph.D., Sheeba K. Thomas, M.D., Donna M. Weber, M.D., Michael Wang, MD, Raymond Alexanian, M.D., Muzaffar H Qazilbash, MD, Uday R Popat, MD, Richard E Champlin, MD, Nina Shah, MD, Qaiser Bashir, MD, Simrit Parmar, MD, Yago Nieto, MD, PhD, Sairah Ahmed, MD, Robert Z. Orlowski, M.D., Ph.D., Jatin J. Shah, M.D.

Blood (2013) 122 (21): 5356.

https://doi.org/10.1182/blood.V122.21.5356.5356

Published: 2013

Journal Articles

Identification Of Tight Junction Protein (TJP)-1 As a Modulator and Biomarker Of Proteasome Inhibitor Sensitivity In Multiple Myeloma

Xing-Ding Zhang, PhD, Veerabhadran Baladandayuthapani, Ph.D., Heather Yan Lin, Ph.D., Bart Barlogie, MD, PhD, Saad Z Usmani, MD, FACP, Lin Yang, Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 123.

https://doi.org/10.1182/blood.V122.21.123.123

Published: 2013

Journal Articles

Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody

Fuliang Chu, PhD, Jason R. Westin, MD, Min Zhang, Ph.D., Lei Feng, Veerabhadran Baladandayuthapani, PhD, Zhiqiang Wang, Rochelle Allen, RN, Michael Wallace, MD, Luis Vence, Laszlo Radvanyi, Larry W. Kwak, MD, PhD, Rinat Rotem-Yehudar, PhD, R Eric Davis, Sattva S. Neelapu, MD

Blood (2012) 120 (21): 162.

https://doi.org/10.1182/blood.V120.21.162.162

Published: 2012

Journal Articles

Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma.

Stephan Joseph Dorkhom, D.O., Shadia Zaman, Ph.D., Sheeba K. Thomas, MD, Raymond Alexanian, M.D., Jatin J. Shah, M.D., Donna M. Weber, M.D., Michael Wang, M.D., Martha L. Anderson, R.N., Veerabhadran Baladandayuthapani, Ph.D., Yan Heather Lin, Ph.D., Min Fu, Ph.D., Christine M. Stellrecht, Ph.D., Claudia Morales de Partovi, B.S., Varsha V. Gandhi, Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2012) 120 (21): 2976.

https://doi.org/10.1182/blood.V120.21.2976.2976

Published: 2012

Journal Articles

Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma.

Seema Rawal, PhD, Nathan Fowler, MD, Min Zhang, Ph.D., Zhiqiang Wang, Ph.D., Tariq Muzzafar, MBBS, Nusrat Harun, MS, Veerabhadran Baladandayuthapani, Ph.D., Rakesh Sharma, Ph.D, David Delgado, Michael Wallace, MD, Carla Heise, PhD, Linda Catherine Lacerte, RN, Felipe Samaniego, M.D., R Eric Davis, M.D, Sattva S. Neelapu, MD

Blood (2012) 120 (21): 2766.

https://doi.org/10.1182/blood.V120.21.2766.2766

Published: 2012

Journal Articles

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Jason R. Westin, MD, Fuliang Chu, PhD, Luis E Fayad, MD, Larry W Kwak, MD, PhD, Nathan H Fowler, MD, Jorge E Romaguera, MD, F.B. Hagemeister, MD, Michelle Fanale, MD, Felipe Samaniego, M.D., Rochelle Allen, RN, Lei Feng, Ph.D, Veerabhadran Baladandayuthapani, PhD, Rinat Rotem-Yehudar, PhD, Sattva Neelapu, MD

Blood (2012) 120 (21): 793.

https://doi.org/10.1182/blood.V120.21.793.793

Published: 2012

Journal Articles

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

Deborah J. Kuhn, Zuzana Berkova, Richard J. Jones, Richard Woessner, Chad C. Bjorklund, Wencai Ma, R. Eric Davis, Pei Lin, Hua Wang, Timothy L. Madden, Caimiao Wei, Veerabhadran Baladandayuthapani, Michael Wang, Sheeba K. Thomas, Jatin J. Shah, Donna M. Weber, Robert Z. Orlowski

Blood (2012) 120 (16): 3260–3270.

https://doi.org/10.1182/blood-2011-10-386789

Published: 2012

Includes: Supplemental data

Journal Articles

Response Before Autologous Hematopoietic Stem Cell Transplantation Is An Important Predictor of Outcome in Multiple Myeloma,

Shatha Farhan, MD, Heather Lin, PhD, Veerabhadran Baladandayuthapani, Nina Shah, MD, Qaiser Bashir, MD, Chitra M Hosing, MD, Uday Popat, M.D., Simrit Parmar, M.D., Yvonne T Dinh, Sofia Qureshi, Gabriela Rondon, MD, Sergio Giralt, MD, Richard Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2011) 118 (21): 4119.

https://doi.org/10.1182/blood.V118.21.4119.4119

Published: 2011

Journal Articles

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

Richard J. Jones, Veerabhadran Baladandayuthapani, Sattva Neelapu, Luis E. Fayad, Jorge E. Romaguera, Michael Wang, Rakesh Sharma, Dajun Yang, Robert Z. Orlowski

Blood (2011) 118 (15): 4140–4149.

https://doi.org/10.1182/blood-2011-03-340323

Published: 2011

Includes: Supplemental data

Journal Articles

Inhibition of Interleukin-6 Signaling with CNTO 328 Sensitizes Plasma Cell Dyscrasias to the Effects of Melphalan in Association with Suppression of Signaling through Protein Kinase B/Akt.

Sally A. Hunsucker, Ph.D., Valeria Magarotto, M.D., Jairo A. Matthews, B.A., Michael Wang, M.D., Veerabhadran Baladandayuthapani, Ph.D., Peter M. Voorhees, M.D., Hong Xie, M.D., Mark Cornfeld, M.D., M.P.H., Jeffrey A. Nemeth, M.D., Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2009) 114 (22): 1836.

https://doi.org/10.1182/blood.V114.22.1836.1836

Published: 2009

Journal Articles

Bortezomib Resistance Is Mediated by Increased Signaling through the Insulin-Like Growth Factor-1/Akt Axis.

Deborah J. Kuhn, Ph.D., Chad C. Bjorklund, Ph.D., Valeria Magarotto, M.D., Jairo A. Matthews, B.A., Michael Wang, M.D., Veerabhadran Baladandayuthapani, Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2009) 114 (22): 2739.

https://doi.org/10.1182/blood.V114.22.2739.2739

Published: 2009

Journal Articles

Activation of the Wnt/β-Catenin Pathway Mediates Lenalidomide Resistance in Multiple Myeloma.

Chad C. Bjorklund, Ph.D., Deborah J. Kuhn, Ph.D., B.Sc., Jairo A. Matthews, B.A., Michael Wang, M.D., Veerabhadran Baladandayuthapani, Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2009) 114 (22): 113.

https://doi.org/10.1182/blood.V114.22.113.113

Published: 2009

NARROW

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity

Mucin 20 (MUC20) Modulates Proteasome Assembly Chaperones through the c-MET Pathway and Is a Biomarker of Proteasome Inhibitor Sensitivity in Myeloma

Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells

Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM)

Expression Of Truncated Protein Tyrosine Phosphatase, Receptor Type, O (PTPROt) Influences Multiple Myeloma Sensitivity To Bortezomib Through Akt Signaling, and Is a Favorable Clinical Prognostic Factor

Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia

Identification Of Tight Junction Protein (TJP)-1 As a Modulator and Biomarker Of Proteasome Inhibitor Sensitivity In Multiple Myeloma

Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody

Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma.

Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma.

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

Response Before Autologous Hematopoietic Stem Cell Transplantation Is An Important Predictor of Outcome in Multiple Myeloma,

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

Inhibition of Interleukin-6 Signaling with CNTO 328 Sensitizes Plasma Cell Dyscrasias to the Effects of Melphalan in Association with Suppression of Signaling through Protein Kinase B/Akt.

Bortezomib Resistance Is Mediated by Increased Signaling through the Insulin-Like Growth Factor-1/Akt Axis.

Activation of the Wnt/β-Catenin Pathway Mediates Lenalidomide Resistance in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only